® system (Millipore, Bedford, MA, U.S.A.).
Chromatography The HPLC system consisted of a Waters pump (model 515), WISP 712 auto sample processor, and a 2487 dual absorbance detector coupled to the Millenium 32 version 3.21 software (Waters, Milford MA, U.S.A.). The analytical column was a Radial-Pak Nova-Pak C 18 column (4 mm, 8ϫ100 mm, Waters) protected by Guard-Pak Inserts Nova-Pak C 18 precolumn. Absorbance was measured at 205 nm and separations were performed at 30 ЊC. The mobile phase consisted of 39% 50 mM phosphate buffer (pH 5.9), 22% methanol and 39% acetonitrile. The assay run time was 30 min with a flow rate of 1.8 ml/min. Drugs were quantified by measuring the peak areas under the chromatograms. We developed a simple HPLC method for the simultaneous quantitative determination of seven HIV protease inhibitors: amprenavir (APV), atazanavir (ATV), indinavir (IDV), lopinavir (LPV), nelfinavir (NFV), ritonavir (RTV), saquinavir (SQV), and a nonnucleoside reverse transcription inhibitor, efavirenz (EFV). This method involves a rapid liquid-liquid drug extraction from plasma, the use of an isocratic elution on a reversed-phase C 18 column, and an ultraviolet detection at a single wavelength (205 nm). The mobile phase consisted of 39% 50 mM phosphate buffer (pH 5.9), 22% methanol and 39% acetonitrile. Forty-eight samples could be measured in one day since the runtime of one sample is 30 min. The assay has been validated over a concentration range of 0.05 to 12.20 m mg/ml for APV, 0.09 to 12.05 m mg/ml for ATV, 0.05 to 12.01 m mg/ml for IDV, 0.12 to 12.36 m m g/ml for LPV, 0.18 to 12.20 m mg/ml for NFV, 0.12 to 12.33 m mg/ml for RTV, 0.12 to 12.06 m mg/ml for SQV, and 0.05 to 12.17 m mg/ml for EFV. Calibration curves were linear in the described concentration ranges. The average accuracy ranged from 97.2 to 106.8%. Both the interday and intraday coefficients of variation for all drugs tested were less than 8.5%. This method provides a simple, accurate, and precise method for the therapeutic drug monitoring of the seven protease inhibitors and EFV in clinical routine use.
Conventional HPLC Method Used for Simultaneous Determination of the Seven HIV Protease Inhibitors and Nonnucleoside Reverse Transcription Inhibitor Efavirenz in Human Plasma
Standard Solutions Stock solutions of all seven protease inhibitors and EFV were prepared by dissolving accurately weighed amounts of each reference compound in water/ethanol (50 : 50, v/v) to yield concentrations of 106.1 mg/ml for APV, 502.0 mg/ml for ATV, 100.1 mg/ml for IDV, 95.1 mg/ml for LPV, 305.0 mg/ml for NFV, 425.0 mg/ml for RTV, 67.0 mg/ml for SQV, and 93.6 mg/ml for EFV. These stock solutions were stored at Ϫ80 ЊC and thawed on the day of analysis. Each stock solution was diluted in drug-free plasma to yield concentrations of 0. 05 Sample Preparation Two milliliters of ethyl acetate/nhexane (50 : 50, v/v) containing the IS (2.02 mg/ml) and 1 ml of 0.5 M sodium carbonate were added to a 500 ml plasma sample. The mixture was vortexed and then centrifuged at 3500ϫg for 5 min. The organic layer was separated and evaporated dry. The dried material was then dissolved in 100 ml of a mobile phase solution and centrifuged at 13000ϫg for 5 min. Lastly, 25 ml of the upper solution was injected into the HPLC column. Before taking peripheral blood, written informed consent was obtained from all patients and a healthy volunteer.
Validation Intraday and interday precision values using this method were estimated by assaying control plasma containing five different concentrations of APV, ATV, IDV, LPV, NFV, RTV, SQV and EFV five times on the same day and on three separate days to obtain the coefficient of variation (CV). Accuracy was determined as the percentage of the nominal concentration. Drug recovery from plasma was evaluated by analyzing triplicate samples with or without extraction. Figure 1A shows the chromatogram of a plasma sample containing 2.12 mg/ml of APV, 2.20 mg/ml of ATV, 2.00 mg/ml of IDV, 1.90 mg/ml of LPV, 3.05 mg/ml of NFV, 1.71 mg/ml of RTV, 3.05 mg/ml of Fig. 1 . Chromatograms Obtained after Extraction of (A) Spiked Plasma Sample Containing 2.12 mg/ml of APV, 2.20 mg/ml of ATV, 2.00 mg/ml of IDV, 1.90 mg/ml of LPV, 3.05 m g/ml of NFV, 1.71 mg/ml of RTV, 3.05 mg/ml of SQV and 1.87 mg/ml of EFV and (B) Drug-Free Human Plasma Sample from a Healthy Volunteer. SQV, and 1.87 mg/ml of EFV. Under the described chromatographic conditions, retention times were 3.4, 4.2, 8.2, 10.5, 13.2, 15.2, 18.0, 24.6, and 9.4 min for APV, IDV, ATV, RTV, LPV, IS, SQV, NFV, and EFV, respectively. At a detection wavelength of 205 nm, assays performed on drug-free human plasma failed to show the presence of any interfering peaks during the interested intervals of the retention times (Fig.  1B) . These results indicated that the established conditions were valid when measuring these drugs simultaneously.
RESULTS

Chromatograms of Plasma Sample
Validation: Linearity, Precision, Accuracy and Recovery Calibration curves of APV, ATV, IDV, LPV, NFV, RTV, SQV and EFV appeared linear in the concentration range of 0.05 to 12.20 mg/ml for APV, 0.09 to 12.05 mg/ml for ATV, 0.05 to 12.01 mg/ml for IDV, 0.12 to 12.36 mg/ml for LPV, 0.18 to 12.20 mg/ml for NFV, 0.12 to 12.33 mg/ml for RTV, 0.12 to 12.06 mg/ml for SQV and 0.05 to 12.17 mg/ml for EFV, with correlations of 1.000, 0.9999, 0.9999, 0.9993, 0.9997, 0.9999, 0.9991, and 0.9999, respectively.
Precision, accuracy, and extraction recovery of our HPLC method are shown in Table 1 . The selected concentration of each drug covers the expected plasma concentrations found in the patients.
The CVs calculated for APV in the intraday and interday assays ranged from 1.4 to 6.5% and 2.0 to 5.2%, respectively. In ATV CVs ranged from 1.2 to 5.6% and 2.0 to 5.0%, and in IDV, CVs ranged from 1.8 to 5.4% and 1.4 to 7.5%. For LPV, CVs ranged from 1.4 to 6.6% and 2.3 to 7.0%, NFV CVs ranged from 0.6 to 8.5% and 2.2 to 8.4%, RTV CVs ranged from 2.5 to 7.8% and 2.3 to 7.5%, SQV CVs ranged from 0.4 to 6.4% and 2.7 to 6.4%, while for EFV the CVs ranged from 2.0 to 3.8% and 2.6 to 6.5%. Accuracies ranged from 97. 8 Figure 2A shows a chromatogram of a plasma sample from an HIV-1-infected patient treated with ATV and RTV. Fig. 2B shows a chromatogram of a plasma sample from an HIV-1-infected patient treated with LPV and RTV. There is no significant drift from the baseline and no interfering peaks affecting quantification of ATV, LPV and RTV in this chromatogram. These results were validated by peak testing and library matching performed with Millenium 32 software.
Chromatograms of Patient Samples
DISCUSSION
There have been some recent reports of HPLC methods for simultaneous determination of antiretroviral drugs. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] However, these methods have several disadvantages in terms of cost performance, time consumption and necessary equipment; for example, the use of expensive disposable cartridges at the solid-phase drug extraction, gradient elution control by a gradient HPLC pump system, and the ultraviolet detection at multiple wavelengths.
We describe the development, validation, and application of a simple HPLC method for simultaneous quantitative determination of seven PIs currently on the market as well as EFV. The principal advantages of our method are a rapid liquid-liquid drug extraction from plasma, an isocratic elution on a reversed-phase C 18 column, and ultraviolet detection at a single wavelength (205 nm).
Generally, the retention time of antiretroviral drugs are dependent on pH of the mobile phase buffer. 14) In fact, some previously reported assays used the mobile phase buffer at a variety of pH values. We sought the optimum pH of the mobile phase buffer by changing pH every 0.5 from pH 2 to pH 11. Finally, we determined pH 5.9 phosphate buffer for the mobile phase to separate each drug. A mobile phase with a pH 9.4 phosphate buffer also enabled excellent drug separation. The overlapping profile of some peaks was not excluded in the pH condition except about 6 and 9.5. However, we recommend pH 5.9 phosphate buffer, because alkaline buffer rapidly degrades the C 18 reversed-phase column and causes a baseline drift. In this study, calibration curves of all the drugs used were linear in the described concentration ranges and the average accuracy ranged from 97.2 to 106.8%. Both interday and intraday CVs for all drugs were less than 8.5%, which is similar to or much lower than previously reported values. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Mean extraction recoveries varied from 81.2% (IDV) to 98.4% (APV). These results indicate that the method developed here achieves a high degree of reproducibility and accuracy.
When antiretroviral drugs are administered at the recommended dose, plasma concentrations are expected in the 0.3 to 8.2 mg/ml range for APV, 12) the 0.2 to 10 mg/ml range for ATV, 17) the 0.1 to 7.7 mg/ml range for IDV, 18, 19) the 5.5 to 9.6 mg/ml range for LPV, 12) the 0.1 to 4.0 mg/ml range for NFV, 18, 20) the 0.1 to 11.2 mg/ml range for RTV, 18, 20) the 0 to 0.2 mg/ml range for SQV, 18) and the 1 to 4 mg/ml range for EFV. 21) Our method successfully covers these regions with good precision and accuracy. Figure 1 illustrates the chromatogram of a plasma sample containing IS, APV, ATV, IDV, LPV, NFV, RTV, SQV, and EFV. Our isocratic elution yields sharp peaks for all the drugs tested and gives an excellent separation for each. The chromatogram of the blank plasma sample shows that there was no significant drift from the baseline and no interfering peaks affecting the quantification of all the drugs. Furthermore, it turns out that no analytical interference was encountered from endogenous substances or other co-administered drugs at the retention time for each drug, even in the chromatogram of a plasma sample from an HIV-1-infected patient treated with either ATV/RTV or LPV/RTV. Therefore, our method can be made available for optimal follow-up of HIV-infected patients through therapeutic drug monitoring.
In conclusion, this simple HPLC method can be conveniently used as a routine clinical application and enables study of the drug pharmacokinetics in conventional hospital laboratories. This method can also offer continuous measurement of 48 samples in one day.
